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ABSTRACT
Objective To determine accuracy, safety and
acceptability of the FreeStyle Libre Flash Glucose
Monitoring System in the paediatric population.
Design, setting and patients Eighty-nine study
participants, aged 4–17 years, with type 1 diabetes were
enrolled across 9 diabetes centres in the UK. A factory
calibrated sensor was inserted on the back of the upper
arm and used for up to 14 days. Sensor glucose
measurements were compared with capillary blood
glucose (BG) measurements. Sensor results were masked
to participants.
Results Clinical accuracy of sensor results versus BG
results was demonstrated, with 83.8% of results in zone
A and 99.4% of results in zones A and B of the
consensus error grid. Overall mean absolute relative
difference (MARD) was 13.9%. Sensor accuracy was
unaffected by patient factors such as age, body weight,
sex, method of insulin administration or time of use (day
vs night). Participants were in the target glucose range
(3.9–10.0 mmol/L) ∼50% of the time (mean
12.1 hours/day), with an average of 2.2 hours/day and
9.5 hours/day in hypoglycaemia and hyperglycaemia,
respectively. Sensor application, wear/use of the device
and comparison to self-monitoring of blood glucose
were rated favourably by most participants/caregivers
(84.3–100%). Five device related adverse events were
reported across a range of participant ages.
Conclusions Accuracy, safety and user acceptability of
the FreeStyle Libre System were demonstrated for the
paediatric population. Accuracy of the system was
unaffected by subject characteristics, making it suitable
for a broad range of children and young people with
diabetes.
Trial registration number NCT02388815.
INTRODUCTION
The beneﬁt of good glycaemic control to complica-
tions of diabetes is well recognised and self-
monitoring of glucose levels is central to improving
and maintaining good glycaemic control.1 2 This
can be challenging in children and young people
due to unpredictable and increased frequency of
food intake, variable patterns of physical activity,
increased rates of intercurrent illness, and psycho-
logical and hormonal challenges of adolescence; all
of which can lead to greater glycaemic variability,
wider glycaemic excursions and more frequent
hypoglycaemia than seen in adults.3–5 Currently,
self-monitoring of glucose for children and young
people involves a ﬁngerprick, four or more times
daily.3 6 The burden of self-monitoring of blood
glucose (SMBG) for patients is well known, and
includes: pain, inconvenience, disturbance for
night-time tests and embarrassment.7–9
Continuous glucose monitoring (CGM) over-
comes some of the burden of SMBG and provides
a continuum of glucose data, including visibility of
night-time glucose, rather than the discrete snap-
shots obtained by SMBG. A recent review of data
from randomised controlled trials on CGM use in
the paediatric population concluded that CGM use
is safe and efﬁcacious.10 However, CGM use in
paediatrics has yielded mixed results on glycaemic
control outcomes. Some studies demonstrated
What is already known on this topic?
▸ Achieving, improving and maintaining optimal
glycaemic control in the paediatric population
is challenging because of wide glucose
variability, including detected and undetected
hypoglycaemia and hyperglycaemia.
▸ Type 1 diabetes exchange data indicate that
the majority (>75%) of children/young people
with diabetes do not meet International Society
for Paediatric and Adolescent Diabetes/
American Diabetes Association guidelines for
glycaemic control (glycated haemoglobin
<58 mmol/mol (7.5%)).37 38
▸ Sensor-based glucose monitoring is underused
owing to cost and acceptability for children and
young people with diabetes.
What this study adds?
▸ The FreeStyle Libre System is safe and accurate
when used by children and young people with
diabetes (4–17 years).
▸ This new sensor-based glucose monitoring
technology, requiring no user calibration, was
highly acceptable to participants/caregivers. It
is anticipated that the system could support
enhanced diabetes management.
▸ Glycaemic variability data for this UK
population of 4–17-year-olds show that these
children/young people spent on average
approximately 50% of the time in euglycaemia.
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improved outcomes11–17 and associated increased beneﬁt with
increased use of CGM.16–19 Others showed little difference
when comparing outcomes following use of CGM and SMBG;
in these the lack of clinical beneﬁt was often attributed to poor
adherence to CGM use and reduced sensor wear.4 19–22
CGM is underused in children and young people, perhaps in
part due to the lack of compelling evidence of the beneﬁt it
may provide. Barriers to CGM use include: sensor insertion on
a weekly basis; skin reactions, discomfort/pain at the insertion
site; frequent alarms especially at night (often turned off due
to alarm fatigue); the need for multiple SMBG tests for calibra-
tion; interference with activities; poor sensor-receiver connect-
ivity causing loss of data; high cost and limited
reimbursement.4 19 23–25 It has been proposed that reducing
these barriers could lead to increased uptake of continuous
sensing by children and young people.25
The FreeStyle Libre System (Abbott Diabetes Care) used in
this study potentially resolves many of the issues that affect
adherence with CGM. It provides comprehensive glucose data
(similar to CGM systems), increased sensor wear duration (up
to 14 days, increasing the time between sensor applications),
and has no requirement for ﬁngerprick calibrations. The reader,
which displays glucose results after scanning over the small
sensor worn on the back of the arm, does not need to be kept
close to the sensor and has no automatic alarms (but can alert
the user to hypo/hyperglycaemia and pending excursions when
detected following a scan). Scanning can be performed as often
as is needed, after each scan the reader displays current sensor
glucose, a trend arrow and 8-hour glucose history. The sensor
automatically stores glucose data every 15 min. Device software
can be used to generate summary glucose reports for review by
the patient at home or in clinic with their healthcare profes-
sional (HCP). These features were not available during the
study; the device was masked to participants and HCPs. The
system is designed to replace SMBG testing for self-management
of diabetes, except during rapidly changing glucose, to conﬁrm
hypoglycaemia, or if symptoms do not match system results.
This study is the ﬁrst to report accuracy, safety and acceptability
of the FreeStyle Libre System in children and young people.
Accuracy of the blood glucose (BG) feature of the system is not
under evaluation here; regulatory approval/Conformité
Européenne (European Conformity marking of the device con-
ﬁrms this feature meets the required industry standards for per-
formance. At the time of the study, the device was approved for
use by adults; it has subsequently been approved for use with
children (with supervision from a caregiver).
METHODS
This prospective, single arm study was conducted across nine
diabetes centres in the UK.
Study participants
Children and young people aged 4–17 years, with type 1 dia-
betes (T1D) or type 2 diabetes treated with multiple daily injec-
tions (MDI) of insulin or continuous subcutaneous insulin
infusion (CSII), and currently testing BG at least two times per
day were eligible to participate. Exclusion criteria included: con-
comitant disease/condition that may compromise patient safety;
other labelling prohibitions; currently using a CGM device; and
known/suspected allergy to medical grade adhesives. Any poten-
tially eligible patient from the general diabetes population at
each study site was invited to participate.
Study design
Participants attended clinic three times. Adverse events (AEs)
were reviewed at every participant contact. Visit 1 included a
physical examination, FreeStyle Libre device training, sensor
insertion and sensor application questionnaire. Participants wore
the sensor (on the back of their upper arm) for up to 14 days
and were asked to perform four capillary BG tests daily using
the BG strip-port on the reader (FreeStyle Optium test strips,
Abbott Diabetes Care), each immediately followed by an inter-
stitial ﬂuid (ISF) glucose sensor measurement (data masked to
participants) to allow comparison of results between sensor and
BG. Visit 2 (days 5, 6, 7 or 8) was a safety monitoring
check-up, data was also uploaded. During the ﬁnal clinic visit
(days 12, 13, 14 or 15), the device was unmasked for subjects to
experience its full functionality, sensors were removed (and the
site inspected for any adverse reactions), data were uploaded
and user questionnaires completed. Three sensor lots were used.
Participants were asked to maintain their pre-existing diabetes
self-management plan throughout the study.
The study (NCT02388815) was conducted in compliance with
the study protocol and International Conference on
Harmonisation Guideline for Good Clinical Practice. Competent
authority (MHRA) and ethics approval was obtained and each
participant or their caregiver gave written, informed consent
prior to participation in the study.
Statistical analyses
For the primary accuracy end point, it was determined that a
minimum sample size of 20 participants was needed to obtain a
95% CI around an estimate of the percentage of results in zone
A of the consensus error grid (CEG) of ±5%. However, a larger
sample size was used in order to compare results to a similar
study performed with adult participants.
Sensor values were compared with temporally matched
(within ±5 min) BG values using a number of methods to evalu-
ate overall accuracy of the system: mean absolute relative differ-
ence (MARD), median absolute relative difference (median
ARD), mean relative difference (MRD), proportion of results
within ±1.1 mmol/L of the BG value for glucose <5.55 mmol/L
and within ±20% of the BG value for glucose ≥5.55 mmol/L
(hereafter %within1.1/20). Mean absolute difference (MAD)
and MARD were used to evaluate accuracy at low and mid to
high glucose ranges, respectively. (MARD, median ARD, MRD
and MAD are all measures of the average difference between
sensor and reference values. MARD and median ARD measure
the size but not the direction (higher/lower) of the differences
compared with the reference (absolute) as a percentage of the
reference value (relative). MAD is similar but just reports the
size of the difference (it is not reported as a percentage); this is
commonly used to assess accuracy at low glucose levels. MRD
measures the size and direction of the difference compared with
the reference as a percentage of the reference value.)
CEG analysis, a tool developed to determine clinical accuracy
of SMBG systems, was used to quantify the clinical accuracy of
the device.26 A grid of different zones deﬁnes the clinical signiﬁ-
cance of any difference between test and reference results, as
outlined in ﬁgure 1A.
Analysis of variance (ANOVA) and simple linear regression
were used to assess whether a range of factors affected sensor
accuracy.
Hypoglycaemia/hyperglycaemia alert features were evaluated
by assessing concordance of sensor alerts obtained within
±15 min of BG results in hypoglycaemic (<3.9 mmol/L) and
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hyperglycaemic (>13.3 mmol/L) ranges. Rates with pending
alerts (ie, those with sensor results within ±10% of the BG
threshold) were also determined.
Measures of glycaemic variability were considered as a sec-
ondary end point of the study. Time in range (TIR) was deﬁned
as glucose results between 3.9 mmol/L and 10.0 mmol/L. A
hypoglycaemic/hyperglycaemic excursion was deﬁned as ≥2
consecutive results outside the predeﬁned range, corresponding
to >15 min.
Safety outcomes were analysed for all participants who
enrolled.
All analyses were performed using SAS software, V.9.2 or
later (SAS Institute, Cary, North Carolina, USA).
Missing data have not been imputed in the statistical analysis.
RESULTS
Eighty-nine participants were enrolled in the study, all with
T1D; 50.6% were male; 56% used CSII and 44% used MDI;
mean age was 10.4 years, with 24 participants aged 4–7 years,
39 aged 8–12 years and 26 aged 13–17 years. Duration of dia-
betes was 4.0±2.8 (0.3, 12.2) years (mean±SD (min, max)) and
HbA1c (glycated haemoglobin) was 60±12 (38, 90) mmol/mol
(7.6±1.1 (5.6, 10.4) %).
Paired sensor-BG results were not available for 2 participants
(1 withdrawal prior to obtaining sensor data, 1 protocol devi-
ation led to no reader BG data); therefore, 87 evaluable partici-
pants were included in the accuracy analyses and 88 were
included in the glycaemic variability analysis. All 89 participants
were included in the safety analyses.
Accuracy performance
For assessment of sensor accuracy against capillary BG there
were 5493 paired sensor-BG results. Overall MARD was
13.9%, median ARD was 10.4%, MRD was 1.7% and the %
within1.1/20 was 82.0%. CEG analysis demonstrated 83.8% of
results in zone A and 99.4% of results in zones A and B (ﬁgure
1A). Sensor results were in good agreement with BG results—
Deming regression: slope=1.03, intercept=−0.23 mmol/L, cor-
relation coefﬁcient=0.95. For paired results at lower glucose
concentrations, with BG<5.55 mmol/L (n=1468), MAD was
0.75 mmol/L; for paired results at higher glucose concentra-
tions, BG 5.55–10.0 mmol/L (n=2090), MARD was 13.5%;
and BG>10.0 mmol/L (n=1935), MARD was 10.6%.
In some sensor systems, a lag is evident between BG and
sensor results, such that sensor results are higher than BG
results when glucose is decreasing and lower than BG results
when glucose is increasing.27 This trend (sensor results higher/
lower than BG when glucose is decreasing/increasing) was not
evident with the FreeStyle Libre System (ﬁgure 1B), demonstrat-
ing that there is little ‘lag’ effect.
There were no statistically signiﬁcant differences in accuracy
detected (ANOVA) for sex (p=0.951), method of insulin administra-
tion (p=0.640), sensor lot (p=0.135) or daytime versus night-time
use (p=0.909), as the percentage of results within CEG zone Awere
similar for the subgroups. Accuracy was also not signiﬁcantly inﬂu-
enced by age or body weight—the regression slopes (for percentage
within CEG zone A vs participant age and weight) were not signiﬁ-
cantly different from zero (p=0.133 and p=0.284, respectively).
The sensor detected hypoglycaemia (when capillary BG
<3.9 mmol/L) on 70% (438/622) of occasions, increasing to
Figure 1 Sensor accuracy: (A) Consensus error grid (CEG) analysis comparing FreeStyle Libre sensor results to capillary blood glucose (BG) results.
(B) Mean relative difference (MRD) of sensor results to capillary BG at different rates of change in glucose concentration (percentages show
proportion of data at each rate of change).
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84% when pending alerts (sensor results within 10% of the
hypoglycaemic threshold) were included. For the 30% of occa-
sions where hypoglycaemia measured in capillary testing was
not detected by the sensor, further analysis of those results for
clinical signiﬁcance using the CEG indicates that 164 were in
zones A and B (clinically acceptable) and 20 were in zone C
(altered clinical action—likely to affect clinical outcome). The
sensor detected hyperglycaemia (when BG >13.3 mmol/L) on
85% of occasions, increasing to 94% when pending alerts were
included (n=999).
Glycaemic variability
Sensor data collected during the study were used to retrospect-
ively determine glycaemic variability of participants during their
time in the study (table 1). Participants were in euglycaemia
(3.9–10.0 mmol/L) ∼50% of the time; this was the same
through day and night, and for both methods of insulin admin-
istration. The relationship of TIR to HbA1c is similar for older
and younger participants (p=0.229 and 0.297 for slope and
intercept, respectively, ﬁgure 2). On average, participants spent
2.2 hours/day and 9.6 hours/day in hypoglycaemia (<3.9 mmol/
L) and hyperglycaemia (>10.0 mmol/L), respectively. The break-
down of glucose excursions through daytime and night-time
periods and for participants using CSII and MDI is shown in
table 1.
Comparison of glycaemic variability observed in this study to
that reported for other studies is made in the online
supplementary material.
User acceptability
Study participants and/or their caregivers rated their experience
with the system on a scale of 0 (strongly agree) to 4 (strongly
disagree). Statements about sensor application (84.3–92.1%),
sensor wear and use (87.2–100%), comparing use to SMBG
(85.4–97.5%) and the device itself (68.3–96.3%) were rated
favourably (0 or 1) by most respondents. Figure 3 summarises
responses by sex, and shows the system was perceived similarly
by both sexes.
Safety
One participant had a serious AE that was not related to the
study or device (pain and lack of feeling in leg). Five device
related AEs were reported in total from ﬁve (6%) participants,
aged 6, 9, 10, 12 and 15 years: allergic reaction, blister, pink
mark/scabbing and abrasion on sensor removal (n=2)—four
were mild, one was moderate, all were resolved at study
completion.
Site exams performed for all sensor insertions checked for
anticipated AEs associated with sensor application or insertion
sites—moderate erythema was observed on 11.6% of occasions,
mild erythema and pain 13.6% and 4.1%, respectively, and mild
instances of bleeding, bruising, itching and oedema were each
on <3% of occasions. There were no trends in rate of antici-
pated AEs, including erythema, with age.
DISCUSSION
This study was the ﬁrst to evaluate performance and usability
of the FreeStyle Libre System in children and has demon-
strated good agreement between sensor and BG results. The
system is unique among ISF glucose monitoring sensors in that
it can be worn for up to 14 days and does not require user
calibration. Comparison of accuracy data from this study to
that from other paediatric studies using ISF glucose sensors
demonstrated that the factory calibrated system provided
similar accuracy to systems requiring daily ﬁngerprick calibra-
tions (table 2). The lack of user calibration eliminates potential
Table 1 Average time in key glycaemic ranges
Time of day Insulin administration
Overall Daytime (6:00–22:00)* Night-time (22:00–6:00)† CSII MDI
n (participants) 88 88 87 50 38
Sensor glucose, mmol/L
Mean (SD) 9.7 (2.0) 9.9 (2.1) 9.2 (2.4) 9.8 (2.0) 9.6 (1.9)
Time in range, hypoglycaemia and hyperglycaemia, hours per day (*per day=16-hour period; †per day=8-hour period)
3.9–10 mmol/L mean (SD) 12.1 (3.7) 8.1 (2.6) 4.1 (1.5) 12.1 (3.6) 12.2 (3.8)
min, max 3.6, 21.0 2.7, 14.3 0.8, 7.7 4.2, 21.0 3.6, 20.0
<3.9 mmol/L mean (SD) 2.2 (2.2) 1.2 (1.3) 1.0 (1.0) 2.0 (1.6) 2.6 (2.8)
min, max 0.0, 13.5 0.0, 9.0 0.0, 5.7 0.1, 6.5 0.0, 13.5
<3.0 mmol/L mean (SD) 0.9 (1.6) 0.4 (0.9) 0.5 (0.7) 0.7 (0.9) 1.3 (2.2)
min, max 0.0, 10.5 0.0, 7.0 0.0, 4.8 0.0, 3.4 0.0, 10.5
>10.0 mmol/L mean (SD) 9.6 (4.2) 6.7 (2.9) 2.9 (1.8) 9.9 (4.4) 9.2 (3.9)
min, max 0.0, 19.5 0.0, 13.1 0.0, 7.2 0.4, 19.5 0.0, 15.4
>13.3 mmol/L mean (SD) 5.2 (3.4) 3.8 (2.5) 1.5 (1.3) 5.3 (3.5) 5.1 (3.3)
min, max 0.0, 14.1 0.0, 10.2 0.0, 5.3 0.0, 14.1 0.0, 11.6
Frequency of hypoglycaemic and hyperglycaemic events per day (24 hours)
<3.9 mmol/L mean (SD) 1.3 (1.0) 1.0 (0.8) 0.5 (0.4) 1.2 (0.9) 1.4 (1.0)
<3.0 mmol/L mean (SD) 0.6 (0.8) 0.4 (0.6) 0.3 (0.3) 0.5 (0.4) 0.7 (1.1)
>10.0 mmol/L mean (SD) 2.6 (0.8) 2.3 (0.7) 0.9 (0.5) 2.7 (0.8) 2.6 (0.8)
>13.3 mmol/L mean (SD) 1.8 (0.8) 1.5 (0.7) 0.6 (0.4) 1.8 (0.8) 1.8 (0.9)
Overall glucose variability
SD, mmol/L 4.5 (1.1) 4.5 (1.1) 4.0 (1.1) 4.4 (0.9) 4.6 (1.2)
Coefficient of variation
(subject level), %
46.5 (7.8) 45.7 (8.0) 43.6 (9.6) 45.2 (7.7) 48.2 (8.1)
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection.
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variations in sensor systems that may be introduced through
errors in BG results used for calibration, calibration
at inappropriate times (during rapidly changing glucose),
missing calibrations or use of sensor rather than BG values for
calibration.31–33
Comparison of results from this study to those from a study
where adults used the system34 shows: MARD versus capillary
BG of 13.9% and 11.4%; percentage in CEG zone A of 83.8%
and 86.7%; and percentage in CEG zones A and B of 99.4%
and 99.7%, in children and adults, respectively. This trend is
similar to that reported for other ISF systems: Dexcom G4
Platinum had MARD versus capillary BG of 15% and 14.0% in
children and adults, respectively.4 35 Similarly, Dexcom G4
Platinum with software 505 algorithm had MARD versus capil-
lary BG of 13% and 11.3% in children and adults,
respectively.4 35
This study has conﬁrmed that sensor accuracy is robust to
patient characteristics such as age, body weight, method of
Figure 2 Time in range versus participant glycated haemoglobin (HbA1c).
Figure 3 User acceptability with paediatric population (participant and caregiver responses to user questionnaires).
547Edge J, et al. Arch Dis Child 2017;102:543–549. doi:10.1136/archdischild-2016-311530
Original article
insulin administration and sex. Accuracy of the system along
with its robustness to differing patient characteristics, are sufﬁ-
cient to recommend its use to paediatric patients as support in
optimising their glycaemic control. The study identiﬁed that
there were 20/622 occasions where hypoglycaemia measured in
capillary testing was not detected by the sensor and CEG ana-
lysis identiﬁed that there may be altered clinical action based on
the sensor result. The product labelling advises patients to use a
BG meter to check the sensor result if symptoms do not match
the sensor result.
This study, providing the ﬁrst glucose variability data for a
paediatric population in the UK, and others,7 13 14 17 21 36 show
there is signiﬁcant opportunity to improve glycaemic control in
children and young people with diabetes. Several studies have
associated improved outcomes with increased sensor wear.16–19
A sensor with a longer wear period, that does not require ﬁnger-
prick calibration, may support more frequent sensor use, and
thus help improve clinical outcomes in children and young
people.
SMBG provides single, intermittent results, which may not
capture intervals of extreme variability or nocturnal events. In
comparison, the system displays the current glucose result, the
last 8 hours of glucose data (including night-time results without
any disturbance to the child) and trend information when the
sensor is scanned—providing signiﬁcantly more data to guide
treatment for this challenging population than routine SMBG.
This study has demonstrated safety and user acceptability of
the system. Device related AEs occurred in 6% of participants,
the same rate was observed in adults.34 The AEs were reported
by participants aged 6–15 years, and thus were not concentrated
in a particular age group. Anticipated sensor application/inser-
tion site symptoms (pain, bleeding, bruising, erythema, itching,
oedema) were reported in 44% of participants (63% of which
were mild in severity), this is similar to the rate observed in
adults,34 where 36% of participants experienced skin issues
(p=0.337). Erythema was the symptom noted most frequently
and, as with other anticipated AEs, was not associated with par-
ticular age groups. Despite these symptoms, results of the user
questionnaires were similar for boys and girls and were largely
favourable, culminating in 96.3% of respondents stating they
would recommend the system to someone else with diabetes.
A limitation of this study is the single body site used.
Additional studies are needed to determine suitability of add-
itional body sites for sensor wear and longer-term studies are
needed to evaluate whether this system can provide improved
adherence with sensor wear and improved glycaemic outcomes
with continued use over time. Exploring alternate reference
methods and more detailed analysis of the glycaemic variability
data using subgroups (eg, age) may be of interest.
CONCLUSIONS
This prospective study has clearly demonstrated the accuracy,
safety and user acceptability of the FreeStyle Libre System for
the paediatric population. Accuracy was unaffected by subject
characteristics, making the system potentially suitable for a
broad range of children and young people with diabetes. It is
anticipated that the provision of comprehensive glucose data for
up to 14 days, from a system that is easy to use, with reduced
pain and burden for the user since there is no requirement for
ﬁngerprick calibration, could support enhanced diabetes man-
agement. Further studies are needed to determine whether
improved outcomes can be achieved with prolonged use of the
system.
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